Browse by UCL Departments and Centres
![[up]](/style/images/multi_up.png)
Up a levelGroup by: Author | Type
Number of items: 59.
Article
AbdulJabbar, K;
Raza, SEA;
Rosenthal, R;
Jamal-Hanjani, M;
Veeriah, S;
Akarca, A;
Lund, T;
... Yuan, Y; + view all
(2020)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
Nature Medicine
, 26
pp. 1054-1062.
10.1038/s41591-020-0900-x.
|
|
Ahern, A;
Griffin, S;
Wheeler, G;
Sharp, S;
Aveyard, P;
Boyland, E;
Halford, J;
(2020)
The effect of referral to an open-group behavioural weight management programme on the relative risk of normoglycaemia, non-diabetic hyperglycaemia and type 2 diabetes: secondary analysis of the WRAP trial.
Diabetes, Obesity and Metabolism
, 22
(11)
pp. 2069-2076.
10.1111/dom.14123.
|
 |
|
Angelis, A;
Naci, H;
Hackshaw, A;
(2020)
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.
Pharmacoeconomics
, 38
pp. 1297-1308.
10.1007/s40273-020-00956-w.
|
|
Bishton, MJ;
Rule, S;
Wilson, W;
Turner, D;
Patmore, R;
Clifton-Hadley, L;
McMillan, A;
... Haynes, A; + view all
(2020)
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
British Journal of Haematology
, 190
(4)
pp. 545-554.
10.1111/bjh.16555.
|
|
Blagden, SP;
Cook, AD;
Poole, C;
Howells, L;
McNeish, IA;
Dean, A;
Kim, J-W;
... Clamp, AR; + view all
(2020)
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
The Lancet Oncology
, 21
(7)
pp. 969-977.
10.1016/S1470-2045(20)30218-7.
|
|
|
Booth, S;
Plaschkes, H;
Kirkwood, AA;
Gibb, A;
Horgan, P;
Higham, C;
Oladipo, JM;
... Eyre, TA; + view all
(2020)
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.
Blood Advances
, 4
(18)
pp. 4337-4346.
10.1182/bloodadvances.2020002553.
|
|
|
Bray, T;
Sakai, N;
Dudek, A;
Fisher, C;
Rajesparan, K;
Lopes, A;
Ciurtin, C;
... Hall-Craggs, M; + view all
(2020)
Histographic Analysis of Oedema and Fat in Inflamed Bone Marrow based on Quantitative MRI.
European Radiology
, 313
10.1007/s00330-020-06785-x.
|
|
|
Brazil, L;
Swampillai, AL;
Mak, KM;
Edwards, D;
Mesiri, P;
Clifton-Hadley, L;
Shaffer, R;
... Short, SC; + view all
(2020)
Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial.
Neuro-Oncology Advances
, 2
(1)
10.1093/noajnl/vdaa046.
|
|
|
Burnett, T;
Mozgunov, P;
Pallmann, P;
Villar, SS;
Wheeler, GM;
Jaki, T;
(2020)
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.
BMC Medicine
, 18
, Article 352. 10.1186/s12916-020-01808-2.
|
|
|
Colombo, I;
Zaccarelli, E;
Del Grande, M;
Tomao, F;
Multinu, F;
Betella, I;
Ledermann, JA;
... Colombo, N; + view all
(2020)
ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies.
ESMO Open
, 5
, Article e000827. 10.1136/esmoopen-2020-000827.
|
|
|
Colombo, N;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Weberpals, JI;
... Coleman, RL; + view all
(2020)
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecologic Oncology
10.1016/j.ygyno.2020.05.045.
(In press).
|
|
Dehbi, H-M;
Hackshaw, A;
(2020)
Sample size calculation in randomised phase II selection trials using a margin of practical equivalence.
Trials
, 21
, Article 301. 10.1186/s13063-020-04248-8.
|
|
|
Elyashiv, O;
Ledermann, J;
Parmar, G;
Farrelly, L;
Counsell, N;
Feeney, A;
El-Khouly, F;
... Nicum, S; + view all
(2020)
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
International Journal of Gynecologic Cancer
10.1136/ijgc-2020-002073.
(In press).
|
|
|
Eyre, TA;
Djebbari, F;
Kirkwood, AA;
Collins, GP;
(2020)
Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
Haematologica
, 105
(7)
pp. 1914-1924.
10.3324/haematol.2019.229948.
|
|
|
Fennell, D;
Danson, S;
Woll, P;
Forster, M;
Talbot, D;
Child, J;
Farrelly, L;
... Wheeler, G; + view all
(2020)
Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02): A phase Ib trial.
Clinical Cancer Research
, 26
(18)
pp. 4748-4755.
10.1158/1078-0432.CCR-20-1306.
|
|
Fenwick, JD;
Landau, DB;
Baker, AT;
Bates, AT;
Eswar, C;
Garcia-Alonso, A;
Harden, SV;
... Counsell, N; + view all
(2020)
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer.
International Journal of Radiation Oncology*Biology*Physics
, 106
(4)
pp. 733-742.
10.1016/j.ijrobp.2019.11.397.
|
|
|
Fox, TA;
Troy-Barnes, E;
Kirkwood, AA;
Chan, WY;
Day, JW;
Chavda, SJ;
Kumar, EA;
... Ardeshna, KM; + view all
(2020)
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'.
British Journal of Haematology
, 191
(3)
pp. 505-506.
10.1111/bjh.17110.
|
|
Fox, TA;
Troy-Barnes, E;
Kirkwood, AA;
Chan, WY;
Day, J;
Chavda, SJ;
Kumar, EA;
... Ardeshna, KM; + view all
(2020)
Clinical outcomes and risk factors for severe COVID‐19 infection in patients with haematological disorders receiving chemo‐ or immunotherapy.
British Journal of Haematology
, 191
(2)
pp. 194-206.
10.1111/bjh.17027.
|
|
Gewandter, JS;
Dworkin, RH;
Turk, DC;
Devine, EG;
Hewitt, D;
Jensen, MP;
Katz, NP;
... Witter, J; + view all
(2020)
Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.
The Journal of Pain
, 21
(9-10)
pp. 931-942.
10.1016/j.jpain.2019.12.003.
|
|
Ghorani, E;
Reading, JL;
Henry, JY;
Massy, MRD;
Rosenthal, R;
Turati, V;
Joshi, K;
... Quezada, SA; + view all
(2020)
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.
Nature Cancer
, 1
(5)
pp. 546-561.
10.1038/s43018-020-0066-y.
|
|
Glynne-Jones, R;
Meadows, HM;
Lopes, A;
Muirhead, R;
Sebag-Montefiore, D;
Adams, R;
ACTII study group;
(2020)
Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus. Results of a post-hoc analysis from the randomized phase III ACT II trial.
Annals of Oncology
, 31
(10)
pp. 1376-1385.
10.1016/j.annonc.2020.06.012.
|
|
Glynne-Jones, R;
Meadows, HM;
Lopes, A;
Riddle, P;
Duggan, M;
Sebag-Montefiore, D;
McDonald, A;
... Adams, R; + view all
(2020)
A Phase I/II Feasibility Study of Intravenous Cetuximab in Combination with 5 days Weekly Oral Capecitabine and Preoperative Radiotherapy in Rectal Cancer (XERXES).
Archives of Clinical and Biomedical Research
, 4
(4)
pp. 394-412.
10.26502/acbr.50170112.
|
|
|
Gourley, C;
Miller, RE;
Hollis, RL;
Ledermann, JA;
(2020)
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Current Opinion in Oncology
, 32
(5)
pp. 442-450.
10.1097/CCO.0000000000000660.
|
|
Grayling, MJ;
Wheeler, GM;
(2020)
A review of available software for adaptive clinical trial design.
Clinical Trials
10.1177/1740774520906398.
(In press).
|
|
|
Hainsworth, EG;
Shahmanesh, M;
Stevenson, F;
(2020)
Insights into the social context of living with a dual diagnosis of HIV and cancer: a qualitative, thematic analysis of popular discourse in London newspapers.
AIDS Care
, 32
(6)
pp. 793-799.
10.1080/09540121.2019.1653444.
|
|
Hall, MR;
Dehbi, H-M;
Banerjee, S;
Lord, R;
Clamp, A;
Ledermann, JA;
Nicum, S;
... Rustin, G; + view all
(2020)
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Gynecologic Oncology
, 159
(3)
pp. 692-698.
10.1016/j.ygyno.2020.09.048.
|
|
Harter, P;
Pautier, P;
Van Nieuwenhuysen, E;
Reuss, A;
Redondo, A;
Lindemann, K;
Kurzeder, C;
... Marme, F; + view all
(2020)
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
International Journal of Gynecologic Cancer
10.1136/ijgc-2020-001572.
(In press).
|
|
|
Hutchison, I;
Hackshaw, A;
(2020)
Reply to Comment(s) on "Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort".
British Journal of Cancer
, 123
pp. 1200-1201.
10.1038/s41416-020-0983-7.
|
|
Illidge, TM;
Phillips, EH;
Counsell, N;
Pettengell, R;
Johnson, PWM;
Culligan, DJ;
Popova, B;
... Radford, J; + view all
(2020)
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma.
Blood Advances
, 4
(1)
pp. 203-206.
10.1182/bloodadvances.2019001023.
|
|
|
Koutoukidis, DA;
Land, J;
Hackshaw, A;
Heinrich, M;
McCourt, O;
Beeken, RJ;
Philpott, S;
... Yong, KL; + view all
(2020)
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
British Journal of Cancer
10.1038/s41416-020-0866-y.
(In press).
|
|
|
Koutoukidis, DA;
Land, J;
Hackshaw, A;
Heinrich, M;
McCourt, O;
Beeken, RJ;
Philpott, S;
... Yong, KL; + view all
(2020)
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
British Journal of Cancer
10.1038/s41416-020-0866-y.
(In press).
|
|
|
Land, J;
McCourt, O;
Heinrich, M;
Beeken, RJ;
Koutoukidis, DA;
Paton, B;
Yong, K;
... Fisher, A; + view all
(2020)
The adapted Zelen was a feasible design to trial exercise in myeloma survivors.
Journal of Clinical Epidemiology
, 125
pp. 76-83.
10.1016/j.jclinepi.2020.04.004.
|
|
|
Lechner, M;
Counsell, N;
Liu, J;
Eynon-Lewis, N;
Paun, S;
Lund, VJ;
Jayaraj, S;
(2020)
Anosmia and hyposmia in health-care workers with undiagnosed SARS-CoV-2 infection.
Lancet Microbe
, 1
(4)
, Article e150. 10.1016/S2666-5247(20)30096-3.
|
|
|
Ledermann, JA;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... Coleman, RL; + view all
(2020)
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncology
, 21
(5)
pp. 710-722.
10.1016/S1470-2045(20)30061-9.
|
|
Lee, A;
(2020)
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer.
Cancer Discovery
, 10
(10)
pp. 1465-1474.
10.1158/2159-8290.CD-20-0773.
|
|
Lee, LYW;
Cazier, J-B;
Starkey, T;
Briggs, SEW;
Arnold, R;
Bisht, V;
Booth, S;
... UK Coronavirus Cancer Monitoring Project Team; + view all
(2020)
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.
The Lancet Oncology
, 21
(10)
pp. 1309-1316.
10.1016/S1470-2045(20)30442-3.
|
|
Litchfield, K;
Reading, JL;
Lim, EL;
Xu, H;
Liu, P;
Al-Bakir, M;
Wong, YNS;
... Swanton, C; + view all
(2020)
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.
Nature Communications
, 11
, Article 3800. 10.1038/s41467-020-17526-5.
|
|
|
Litchfield, K;
Stanislaw, S;
Spain, L;
Gallegos, LL;
Rowan, A;
Schnidrig, D;
Rosenbaum, H;
... Turajlic, S; + view all
(2020)
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
Cell Reports
, 31
(5)
p. 107550.
10.1016/j.celrep.2020.107550.
|
|
López, S;
Lim, EL;
Horswell, S;
Haase, K;
Huebner, A;
Dietzen, M;
Mourikis, TP;
... McGranahan, N; + view all
(2020)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution.
Nature Genetics
, 52
(3)
pp. 283-293.
10.1038/s41588-020-0584-7.
|
|
McLeavy, L;
Rahman, B;
Kristeleit, R;
Ledermann, J;
Lockley, M;
McCormack, M;
Mould, T;
... Lanceley, A; + view all
(2020)
Mainstreamed Genetic Testing in Ovarian Cancer: Patient Experience of the Testing Process.
International Journal of Gynecological Cancer
, 30
(2)
pp. 221-226.
10.1136/ijgc-2019-000630.
|
|
McMillan, AK;
Phillips, EH;
Kirkwood, AA;
Barrans, S;
Burton, C;
Rule, S;
Patmore, R;
... Linch, DC; + view all
(2020)
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
Annals of Oncology
10.1016/j.annonc.2020.05.016.
(In press).
|
|
|
McNamara, MG;
Lopes, A;
Wasan, H;
Malka, D;
Goldstein, D;
Shannon, J;
Okusaka, T;
... Valle, JW; + view all
(2020)
Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer.
Journal of Hepatology
, 73
(5)
pp. 1109-1117.
10.1016/j.jhep.2020.05.014.
|
|
Miller, RE;
Leary, A;
Scott, CL;
Serra, V;
Lord, CJ;
Bowtell, D;
Chang, DK;
... Yates, LR; + view all
(2020)
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Annals of Oncology
, 31
(12)
pp. 1606-1622.
10.1016/j.annonc.2020.08.2102.
|
 |
|
Mirza, MR;
Benigno, B;
Dørum, A;
Mahner, S;
Bessette, P;
Barceló, IB;
Berton-Rigaud, D;
... Matulonis, UA; + view all
(2020)
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Gynecologic Oncology
10.1016/j.ygyno.2020.09.006.
(In press).
|
|
|
Mitchell, E;
Goodman, K;
Hartley, S;
Hickey, H;
McDonald, AM;
Meadows, HM;
Rhodes, S;
... UK Trial Managers’ Network Executive Group; + view all
(2020)
Where do we go from here? – Opportunities and barriers to the career development of trial managers: a survey of UK-based trial management professionals.
Trials
, 21
, Article 384. 10.1186/s13063-020-04316-z.
|
|
|
Moorman, AV;
Schwab, C;
Winterman, E;
Hancock, J;
Castleton, A;
Cummins, M;
Gibson, B;
... Vora, A; + view all
(2020)
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion.
British Journal of Haematology
10.1111/bjh.17093.
(In press).
|
|
|
Newton, C;
Nordin, A;
Rolland, P;
Ind, T;
Larsen-Disney, P;
Martin-Hirsch, P;
Beaver, K;
... Fotopoulou, C; + view all
(2020)
British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU).
International Journal of Gynecologic Cancer
, 30
(5)
pp. 695-700.
10.1136/ijgc-2019-001176.
|
|
|
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
Weberpals, JI;
... Coleman, RL; + view all
(2020)
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Journal of Clinical Oncology
10.1200/JCO.19.03107.
(In press).
|
 |
|
Pilotti, C;
Greenwood, J;
Moss, SE;
(2020)
Functional Evaluation of AMD-Associated Risk Variants of Complement Factor B.
Investigative Opthalmology & Visual Science
, 61
(5)
, Article 19. 10.1167/iovs.61.5.19.
|
|
|
Pinato, DJ;
Lee, AJX;
Biello, F;
Seguí, E;
Aguilar-Company, J;
Carbó, A;
Bruna, R;
... Gennari, A; + view all
(2020)
Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe.
Cancers
, 12
(7)
, Article 1841. 10.3390/cancers12071841.
|
|
|
Roncolato, FT;
O'Connell, R;
Joly, F;
Lanceley, A;
Hilpert, L;
Buizen, L;
Okamoto, E;
... Friedlander, ML; + view all
(2020)
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(> 3) chemotherapy – the GCIG Symptom Benefit Study (SBS).
Gynecologic Oncology
, 156
(1)
pp. 45-53.
10.1016/j.ygyno.2019.10.001.
|
|
Shah, V;
Sherborne, AL;
Johnson, DC;
Ellis, S;
Price, A;
Chowdhury, F;
Kendall, J;
... on behalf of NCRI Haematology Clinical Studies Group; + view all
(2020)
Predicting ultrahigh risk multiple myeloma by molecular profiling:
an analysis of newly diagnosed transplant eligible myeloma XI trial
patients.
Leukemia
10.1038/s41375-020-0750-z.
|
|
|
Sng, CCT;
Wong, YNS;
Wu, A;
Ottaviani, D;
Chopra, N;
Galazi, M;
Benafif, S;
... Shaw, H; + view all
(2020)
Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience.
Frontiers in Oncology
, 10
, Article 595804. 10.3389/fonc.2020.595804.
|
|
|
Tan, WS;
Teo, CH;
Chan, D;
Ang, KM;
Heinrich, M;
Feber, A;
Sarpong, R;
... DETECT II trial collaborators, .; + view all
(2020)
Exploring patients’ experience and perception of being diagnosed with bladder cancer: A mixed methods approach.
BJU International
, 125
(5)
pp. 669-678.
10.1111/bju.15008.
|
|
|
Tjokrowidjaja, A;
Lee, CK;
Friedlander, M;
Gebski, V;
Gladieff, L;
Ledermann, J;
Penson, R;
... Pujade-Lauraine, E; + view all
(2020)
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
European Journal of Cancer
, 139
pp. 59-67.
10.1016/j.ejca.2020.08.021.
|
|
Waterhouse, JV;
Hull, JH;
Linch, M;
(2020)
Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?
European Urology
10.1016/j.eururo.2020.04.027.
(In press).
|
|
|
Zakeri, K;
Rotolo, F;
Lacas, B;
Vitzthum, LK;
Le, Q-T;
Gregoire, V;
Overgaard, J;
... MARCH/MACH-NC Collaborative Group and the Head and Neck Cancer I; + view all
(2020)
Predictive classifier for intensive treatment of head and neck cancer.
Cancer
, 126
(24)
pp. 5263-5273.
10.1002/cncr.33212.
|
Working / discussion paper
|
Laszlo, HE;
Seward, E;
Ayling, R;
Lake, J;
Malhi, A;
Hackshaw, A;
Stephens, C;
... Machesney, M; + view all
(2020)
Quantitative faecal immunochemical test for patients with 'high risk' bowel symptoms: a prospective cohort study.
MedRxiv: Cold Spring Harbor, NY, USA.
|
Thesis
|
Watkins, Thomas Benjamin Kingdon;
(2020)
The role of chromosomal instability and parallel evolution in cancer.
Doctoral thesis (Ph.D), UCL (University College London).
|
